Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01361711 · ClinicalTrials.gov registry record · Phase 2
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
A Phase 2 study of Stage I Chronic Lymphocytic Leukemia and Stage II Chronic Lymphocytic Leukemia, sponsored by Northwestern University.
- Active
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 2
- Study locations
NCT01361711 is a Phase 2 study of Stage I Chronic Lymphocytic Leukemia and Stage II Chronic Lymphocytic Leukemia that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 53 participants, below the 206-participant average among 3 other Stage I Chronic Lymphocytic Leukemia trials with a reported enrollment target (74% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01361711, a Phase 2 study of Stage I Chronic Lymphocytic Leukemia and Stage II Chronic Lymphocytic Leukemia, is active but no longer recruiting, sponsored by Northwestern University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies the side effects and how well giving alemtuzumab and ofatumumab together works in treating patients with previously untreated chronic lymphocytic leukemia (CLL). Monoclonal antibodies, such as alemtuzumab and ofatumumab, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer killing substances to them. Giving alemtuzumab together with ofatumumab may kill more cancer cells
Conditions Studied
Interventions
- PROCEDURE biopsy
- BIOLOGICAL alemtuzumab
- BIOLOGICAL ofatumumab
Study Locations (2)
Illinois
- Northwestern University - Chicago
Other
- Karolinska University Hospital Solna - Stockholm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2011-06 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01361711
The ClinicalTrials.gov registry entry for NCT01361711 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 206-participant average among 3 other Stage I Chronic Lymphocytic Leukemia trials with a reported enrollment target (74% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Stage I Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which biopsy is the first listed.
NCT01361711 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Other.
Frequently Asked Questions
What is clinical trial NCT01361711 about?
NCT01361711 is a clinical study titled "Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia". This phase II trial studies the side effects and how well giving alemtuzumab and ofatumumab together works in treating patients with previously untreated chronic lymphocytic leukemia (CLL). Monoclonal antibodies, such as alemtuzumab and ofatumumab, can block cancer growth in different ways. Some blo...
What is the current status of trial NCT01361711?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2011-06. Estimated completion is 2027-05.
What conditions does trial NCT01361711 study?
This clinical trial studies the following conditions: Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia.
What interventions are being tested in trial NCT01361711?
The interventions under investigation include: biopsy (PROCEDURE), alemtuzumab (BIOLOGICAL), ofatumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01361711?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01361711 being conducted?
This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage I Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
ACTIVE NOT RECRUITING · Phase 3
-
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
COMPLETED · Phase 1
Explore more on PlainTrial
Stage I Chronic Lymphocytic Leukemia
All registered trials for this condition
Stage II Chronic Lymphocytic Leukemia
All registered trials for this condition
Illinois
All trials with a study site in Illinois
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.